Recent Updates
Recently added Catalysts
CMPS Positive Sentiment

Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360

Key Takeaway: Strata Mental Health Solutions has received a grant from Compass Pathways to develop training programs for healthcare providers regarding COMP360, an investigational psilocybin treatment. This initiative aims to prepare clinical networks for the potential delivery of psychedelic treatments. The collaboration highlights Strata's expertise in the field.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strata awarded a significant training grant from Compass Pathways.
  • Development of training programs for innovative psilocybin treatment.
  • Collaboration with experienced founders enhances credibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~32 mo
Minimal dilution risk
Lead asset
Psilocybin
Phase 3 · Major Depressive Disorder

Full Press Release Details

ATLANTA--(BUSINESS WIRE)--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been awarded one of the five U.S. HCP training grants awarded by Compass Pathways (Nasdaq: CMPS) to develop U.S. health care provider training programs for COMP360, Compass’ investigational psilocybin treatment, if approved. Strata’s founders worked with Compass on the development of the provider traini

Frequently Asked Questions

What is COMP360?

COMP360 is an investigational psilocybin treatment developed by Compass Pathways.

Who awarded the training grant to Strata?

The training grant was awarded by Compass Pathways.

What will the grant be used for?

The grant will be used to develop training programs for healthcare providers.

What is the focus of Strata's training programs?

The training programs will focus on preparing providers for psychedelic treatments.

Last updated: Sep 11, 2026